Efficacy of fludarabine and mitoxantrone (FN) combination regimen in untreated indolent non-Hodgkin's lymphomas-Reference-Cited by-同舟云学术

Efficacy of fludarabine and mitoxantrone (FN) combination regimen in untreated indolent non-Hodgkin's lymphomas

Published:2000-03 Issue:3 Volume:11 Page:363-366
ISSN:0923-7534
Container-title:Annals of Oncology
language:en
Short-container-title:Annals of Oncology

Author:

Zinzani P.L.,Magagnoli M.,Bendandi M.,Gherlinzoni F.,Fraternali Orcioni G.,Cellini C.,Stefoni V.,Pileri S.A.,Tura S.

Publisher

Elsevier BV

Subject

Oncology,Hematology

Link

http://academic.oup.com/annonc/article-pdf/11/3/363/19478498/11-3-363.pdf

Reference8 articles.

1. Phase 11 trial of fludarabine phosphate in lymphoma: An effective new agent in low-grade lymphoma;Redman;J Clin Oncol,1992

2. Activity of fludarabine in previously treated non-Hodgkin's low-grade lymphoma: Results of an Eastern Cooperative Oncology Group study;Hochster;J Clin Oncol,1992

3. Fludarabine, mitoxantrone, and dexamethasone: An effective new regimen for indolent lymphoma;McLaughlin;J Clin Oncol,1996

4. Fludarabine-mitoxantrone combination-containing regimen in recurrent low-grade non-Hodgkin's lymphoma;Zinzani;Ann Oncol,1997

5. Zinzani PL, Magagnoli M, Moretti L et al. Randomized trial of fludarabine versus fludarabine and idarubicin as front-line treatment in patients with indolent or mantle-cell lymphoma. J Clin Oncol (in press).

Cited by 35 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Pentostatin, cyclophosphamide and rituximab for previously untreated advanced stage, low-grade B-cell lymphomas;British Journal of Haematology;2015-03-31

2. Individualized management of follicular lymphoma;CHIN CLIN ONCOL;2015

3. Fludarabine-Mitoxantrone-Rituximab regimen in untreated indolent non-follicular non-Hodgkin's lymphoma: experience on 143 patients;Hematological Oncology;2014-07-02

4. Extranodal marginal zone B-cell lymphoma of the lung: experience with fludarabine and mitoxantrone-containing regimens;Hematological Oncology;2012-12-05

5. Management of indolent lymphoma: Where are we now and where are we going;Blood Reviews;2012-11